Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.96 USD
-0.15 (-1.35%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHAR 10.96 -0.15(-1.35%)
Will PHAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
New Strong Buy Stocks for August 1st
Best Momentum Stocks to Buy for July 25th
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 25th
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
Other News for PHAR
Pharming (PHAR) Stock Target Raised by Oppenheimer Following Q2 Results
Pharming price target raised by $1 at Oppenheimer, here's why
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M